Business Wire

QUECTEL-WIRELESS

10.1.2024 18:01:36 CET | Business Wire | Press release

Share
Quectel announces industry-first certification of satellite communication module on Skylo network

CES – Quectel Wireless Solutions, a global IoT solutions provider, is pleased to announce the successful certification of Quectel's NTN-enabled module, the CC660D-LS, for use on the network by Skylo, the leading non-terrestrial network (NTN) service provider. The module is the first to be certified by Skylo for use on its network and enables seamless and reliable IoT-NTN connectivity for any standard device that incorporates the module and has a view of the sky.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240110653580/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Quectel announces industry-first certification of satellite communication module on Skylo network (Photo: Business Wire)

Quectel has developed the CC660D-LS module specifically to provide dependable and efficient, two-way, satellite communication capabilities. With the module's certification on the Skylo network, businesses and organizations can harness the power of Skylo's ubiquitous satellite connectivity to enable IoT applications in remote and challenging environments, ensuring that data is transmitted securely and reliably.

The CC660D-LS module provides a range of flexible connectivity options, encompassing L-band, S-band, and Band 23 connections. Notably, this module is equipped to support 3GPP Release 17 IoT non-terrestrial network (IoT-NTN) connections, reflecting its advanced capabilities. Prioritizing reliable connectivity, the CC660D-LS module excels in facilitating two-way communication. Furthermore, the module extends its support to both IP and Non-IP service networks. This dual capability ensures not only enhanced connectivity but also heightened service availability. The CC660D-LS module stands as a comprehensive solution for robust and versatile connectivity needs.

"We are delighted that Skylo has certified our NTN Satellite Communication Module for its network," said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "This certification reflects our commitment to delivering high-quality satellite communication solutions to our customers worldwide. By collaborating with Skylo, we enable businesses to unlock new opportunities and achieve their IoT goals, regardless of where they are located."

The Skylo certification process involved rigorous testing and evaluation to ensure that the CC660D-LS module meets stringent quality and performance standards, including 3GPP Release-17 standards and Skylo's Standards Plus qualifications. Skylo's network is designed to provide global coverage, ensuring that IoT devices equipped with Quectel's module can stay connected in areas with limited terrestrial infrastructure.

"We are excited to welcome Quectel's CC660D-LS module to our ecosystem of certified devices," said Dr Andrew Nuttall, CTO and Co-Founder of Skylo. "This certification is a testament to our commitment to providing the most reliable and expansive satellite based IoT connectivity. By partnering with industry leaders like Quectel, we empower device manufacturers of all types to expand their IoT applications, add additional review streams, and deliver a superior customer experience that requires no change in user behavior."

Quectel's CC660D-LS module is suitable for a wide range of applications, including asset tracking, fleet management, agriculture, maritime, and more. The module's compact design and low-power consumption make it an ideal choice for battery-powered IoT devices that require long-term, uninterrupted connectivity.

Quectel’s IoT modules are developed with security at the core. From product architecture to firmware/software development, Quectel incorporates leading industry practices and standards, mitigating potential vulnerabilities with third party independent test houses and have incorporated security practices like generating SBOMs and VEX files as well as performing firmware binary analysis into the entire software development lifecycle.

IoT developers now can streamline their development process by combining Quectel modules with Quectel's antennas and pre-certification services, effectively reducing both costs and time-to-market for their IoT devices. For the CC660D-LS satellite module, Quectel offers the YECN028AA and YFCA011AA antennas, providing developers with versatile options to enhance connectivity and expedite the deployment of their innovative solutions.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

About Skylo

Skylo Technologies is an NTN service provider based in Mountain View, CA, offering a service that allows cellular modems and devices to connect directly over existing satellites. Devices connected over satellite are managed and served by Skylo’s commercial NTN vRAN, featuring a 3GPP standards-based cloud-native base station and core. Skylo works with existing satellite operators, terrestrial mobile network operators, and device makers to provide subscribers an anywhere, anytime connectivity solution that seamlessly roams between terrestrial and satellite networks. Skylo’s focus is on enabling connected services for people outdoors and connected workflows for machines at work across critical industries such as agriculture, maritime, logistics, mining, and others, in addition to mass-market consumer devices. For more information, visit www.skylo.tech, contact info@skylo.tech, or follow us on LinkedIn and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240110653580/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye